J Clin Invest. 2020. https://doi.org/10.1172/JCI133270.
Introduction
Neuropathic pain conditions arising from injuries to the nervous system due to trauma, disease or neurotoxins are chronic, severe, debilitating and exceedingly difficult to treat (1). Opioids are widely used to treat chronic pain but limited by severe side effects and strong abuse liability (2) . Neuropathic pain is a burgeoning global medical issue (e.g., >15 million people in the US (3) and >20% of the European population (4)) with a profound annual economic burden of treatment (5) . When combined with over 15 million people worldwide having experienced an opioid use disorder (6) , a high priority has been placed upon developing novel non-opioid based analgesics.
GPCRs are the most abundant receptor family and regulate a diverse array of cellular functions, including neurotransmission in pain (7) . Approximately 120 of 400 nonsensory GPCRs are considered oGPCRs as their cognate ligands are unknown (8) . Using a multidisciplinary approach, we present the first evidence that the oGPCR GPR160 in the spinal cord plays critical roles in the development and maintenance of hypersensitivity associated with traumatic nerve injury-induced neuropathic pain. We also identify CARTp (9) as a GPR160 ligand and unraveled signaling pathways engaged downstream of GPR160. These findings provide the foundation for investigating GPR160 as a potential therapeutic target for treating chronic pain.
Results and Discussion
GPR160 is upregulated in the spinal cord during neuropathic pain Our receptomic approach (10) (Supplemental Figure 1A ) identified 4 main clusters (Supplemental Figure 1B ) among non-orphan GPCRs known to be altered in neuropathic pain states (11, 12) . Querying the sequence homology of oGPCRs against GPCRs in these clusters identified 31 candidate oGPCRs (Supplemental Figure 1C ). We surveyed their expression in the spinal cord from rats with chronic constriction of the sciatic nerve (CCI)-induced neuropathic pain, which produces mechano-hypersensitivities that peak by d7 and lasts for several weeks (13) . PCR and quantitative PCR analyses of these oGPCRs revealed that Gpr160 significantly increased in the dorsal, but not the ventral, horn of the spinal cord ipsilateral to injury ( Figure 1A) . As a control, Gpr107, which is expressed in the dorsal horn of the spinal cord but not homologous to any of our branch clusters, was not significantly changed by CCI ( Figure 1A ). No significant changes in Gpr160 were observed in the dorsal root ganglia (n=3; p=0.5).
RNA-Seq analyses of ipsilateral rat DH-SC following CCI or SHAM injury identified 60 differential expressed GPCRs between CCI and SHAM groups. Remarkably, Gpr160 was one of the Gpr transcripts with the greatest differential expression (4.44-fold change; false discovery rate = 6.06x10 -12 ) in the CCI group ( Figures 1B,C) .
GPR160 is highly conserved among species and expressed on neurons, astrocytes and microglia (14, 15) in human and rodent CNS, including the spinal cord (15, 16) . Image analyses of spinal cord from rats with CCI revealed increased GPR160 (26.9%±5.6%SEM; n=5/group; p=0.042; paired t-test; Figure 1D ) and Gpr160 ( Figure 1E Figures 2C and 3D ), Gpr160 was significantly increased in proximity to Aif1 ( Figure 1G ), but not Gfap (Supplemental Figure   2B ) or Rbfox3 (Supplemental Figure 2D ); suggesting microglia may account for CCIinduced Gpr160 and GPR160 expression in the spinal cord.
Activation of GPR160 in the spinal cord contributes to neuropathic pain
The functional contribution of GPR160 at this site was tested using genetic (siRNA) and immunopharmacological (neutralizing antibody) approaches, since there are no small molecule GPR160 antagonists. Daily i.th. injections of siGpr160, but not control siRNA (sieGfp), blocked mechano-allodynia in the rat CCI model ( Figure 2A ) and a second rat model of traumatic nerve injury (spared nerve injury, SNI (17); Figure 2B ). Moreover, i.th. siGpr160 at a time of peak CCI-induced mechano-allodynia (d7 and d8) significantly reversed allodynia ( Figure 2C ) and reduced Gpr160 in the ipsilateral DH-SC by approximately 40% (n=5). Intrathecal injection of neutralizing GPR160 antibody (GPR160 ab) at a time of peak neuropathic pain (d8) also reversed mechano-and cold-allodynia in male rats by 30min with peak reversal effects by 2h (shown in Figures 2D,E) and resolution by 6h. Similar results were obtained in female rats ( Figure 2F ). GPR160 inhibition did not produce observable adverse health effects or alter normal nociceptive thresholds (tail flick latency (18)) in non-injured rats ( Figure 2G ). These results suggest selective alleviation of chronic pain states without impact on beneficial and protective nociceptive responses.
We examined the effect of GPR160 ab on neuronal processing within the spinothalamic-ventrobasal-somatosensory cortical pathway to peripherally applied sensory modalities using in vivo electrophysiological recordings from the ventral posterolateral thalamus (Supplemental Figure 4A ), a key relay in the sensory discriminative pathways of pain in the brain. Baseline evoked and ongoing neuronal activities were comparable to our previous observations (19) . Intrathecal GPR160 ab produced modality-selective inhibitory effects similar to pregabalin (19) in rats with spinal nerve ligation (SNL) that were dependent on the pathophysiological state; similar to behavior and demonstrative of sensory processing rather than motor responses. When compared to baseline, the neuronal responses to punctate mechanical stimuli following GPR160 ab were reduced to a range of low intensity von Frey filaments (2 and 8 g) and those likely to exceed withdrawal thresholds (>15g); whereas, there were no changes Figure 4 ). These results show that GPR160 in spinal cord contributes to the ascending transmission of sensory inputs within sensorydiscriminative projection pathways. The lack of effect in sham animals and on thermal and ongoing activity indicates a selective role of GPR160 inhibition in these pathophysiological evoked responses that is similar to pregabalin (19) . One discrepancy between the behavioral and neuronal data was the lack of effect in cold responses of the sensory neurons. This may be due to the complexities of cold processing and the suprathreshold nature of the neuronal cold stimulus that might employ different molecular mechanisms between behavioral and electrophysiological tests. Differences between the models used may also contribute. The neuronal responses extend to suprathreshold stimuli and so represent coding of high intensity stimuli that could equate better to high pain scores in patients with neuropathy than threshold responses that can be measured in behavioral studies (20) .
CARTp -a ligand of GPR160
Comparing tissue expression profiles (NCBI Gene) of GPR160 and endogenously expressed orphan ligands revealed high correlation between GPR160 and CARTp. (22, 23) . Using cell culture, we de-orphanized GPR160 by identifying a functional and potential physical connection between CARTp and GPR160.
In human KATOIII cancer cells that express GPR160 (Supplemental Figure 5A ), CARTp induced cFOS expression, which was completely blocked in siGpr160-transfected cells ( Figure 3A ). Rat pheochromocytoma cells (PC-12), which can be differentiated into a neuronal-like phenotype, expressed GPR160 (Supplemental Figures 5B,C) . CARTp stimulated ERK phosphorylation (pERK) in PC-12 cells that was attenuated in siGpr160transfected cells ( Figure 3B ). The efficacy of siRNA was confirmed by reduced Gpr160 and GPR160 (Supplemental Figures 5B,C) . These findings suggest a functional relationship between CARTp and GPR160 and reveals GPR160 confers CARTp-induced cFOS and phosphorylation of ERK. Moreover, CARTp co-immunoprecipitated with GPR160 ( Figure 3C ), suggesting a potential physical interaction. The 75 kDa complex is greater than the predicted 52 kDa complex and may reflect additional proteins that associate to form the signalosome. We also found exogenous CARTp co-localized to GPR160 ( Figure 3D-F) . We have previously demonstrated that GPR160 does not interact with another peptide hormone, proinsulin C-peptide (24); suggesting the potential CARTp-GPR160 interaction is likely specific.
CARTp is expressed in the CNS, including the superficial laminae of the rat spinal cord (25, 26) . Cartp is expressed in mouse cerebral cortex glia (microglia and astrocytes) and neurons (14) . However, the contribution of CARTp/GPR160 signaling to nociceptive processing is not known. An i.th. injection of a neutralizing CARTp antibody (CARTp ab) CARTp in pain were inconclusive due in part to limited data and contradictory pro-and anti-nociceptive effects in the CNS (25, 27, 28) . Reported antinociceptive effects of CARTp manifested at very high doses of the peptide (µg) and the purity of the peptide preparation was not known or not reported (27, 28) . In contrast, Ohsawa and colleagues reported that i.th. injections of low dose (3-100 ng), highly purified (>96%) CARTp induced thermal hyperalgesia in a dose-dependent fashion (25) . Using the same purity of CARTp and supplier as Ohsawa, a single i.th. injection of CARTp (3-30ng) in mice caused profound mechano-allodynia in pilot studies that peaked by 1h and persisted over 5h. As shown in Figure 4A , CARTp (30 ng) caused near-to-maximal allodynia by 1h that was abolished by i.th. injection of GPR160 ab ( Figures 4A and B) or CARTp ab ( Figure 4C ), providing support that CARTp-induced mechano-hypersensitivity is dependent on GPR160.
CARTp-induced ERK signaling stimulates the phosphorylation and activation of CREB independently of cAMP signaling (22) . ERK can serve as an upstream regulator of CREB phosphorylation (pCREB) (29) during the development of neuropathic pain (30) . We found i.th. CARTp induced GPR160-mediated ERK/CREB signaling in the mouse DH-SC that contributed to the development of mechano-allodynia. First, i.th. CARTp induced the phosphorylation of ERK ( Figure 4D ) and CREB ( Figure 4E ), which was attenuated by coadministration of GPR160 antibody (Figures 4D,E) . Secondly, inhibiting MAPK/ERK kinases (MEK) 1 and 2 with the MEK1/2 inhibitor, U0126 (31), attenuated CARTp-induced mechano-allodynia ( Figure 4F ) and phosphorylation of ERK ( Figure 4D ) and CREB ( Figure 4E ). Finally, CARTp-induced mechano-allodynia ( Figure 4F ) and CREB 666-15 (32) .
Using an array of multidisciplinary approaches, we found a role for CARTp/GPR160 signaling ( Figure 4G ) in spinal cord in neuropathic pain. These findings provide the kernel for future investigation of GPR160 signaling in pain and other CARTp-associated diseases, including anxiety and depression, reward and addiction, food intake and maintenance of body weight (21) . Accordingly, our findings set the stage for medicinal discovery efforts to identify small molecule antagonists of GPR160 for the treatment of neuropathic pain with broader implication for the treatment of additional disease states.
Methods
Detailed methods are provided in the Supplemental Materials. 
